UCB’s Bimzelx outpacing AbbVie’s Rinvoq, Skyrizi on awareness early in psoriatic arthritis launch: survey
14th February 2025 Uncategorised 0UCB’s Bimzelx is firmly on physicians’ radars, with Spherix Global Insights finding that awareness of the drug was tracking ahead of AbbVie’s Rinvoq and Skyrizi three months into its psoriatic arthritis launch. Yet, the analysis suggests UCB has work to do to turn awareness into uptake.
More: UCB’s Bimzelx outpacing AbbVie’s Rinvoq, Skyrizi on awareness early in psoriatic arthritis launch: survey
Source: fierce